Table 1 Demographics and baseline characteristics
| Â | AAT(II) (N = 34) | OAA (N = 34) | Total (N = 68) |
|---|---|---|---|
Age (year) | 71.4 (6.4) | 70.6 (7.9) | 71.0 (7.1) |
Height (cm) | 166.9 (7.8) | 166.9 (5.8) | 166.9 (6.8) |
Weight (kg) | 69.1 (14.3) | 67.5 (11.6) | 68.3 (12.9) |
BMI (kg/m2) | 24.6 (3.5) | 24.1 (3.3) | 24.4 (3.3) |
ECOG performance status, n (%) | |||
 0 | 7 (20.6) | 12 (35.3) | 19 (27.9) |
 1 | 27 (79.4) | 22 (64.7) | 49 (72.1) |
Serum testosterone level (ng/dL) | 11.3 (10.5) | 9.5 (4.3) | 10.4 (8.0) |
PSA concentration (ng/mL) | 119.5 (225.4) | 435.7 (1423.0) | 277.6 (1023.6) |
Course of disease (month)a | 30.9 (29.0) | 28.4 (26.8) | 29.6 (27.7) |
Gleason score | 8.3 (1.0) | 8.3 (1.1) | 8.3 (1.0) |
Metastatic organ sites, n (%) | |||
 1 | 18 (52.9) | 22 (64,7) | 40 (58.8) |
 2 | 11 (32.4) | 7 (20.6) | 18 (26.5) |
 3 | 1 (2.9) | 3 (8.8) | 4 (5.9) |
 ≥ 4 | 4 (11.8) | 2 (5.9) | 6 (8.8) |
Medical history, n (%) | |||
 Hypertension | 12 (35.3) | 10 (29.4) | 22 (32.4) |
 Aortic atherosclerosis | 3 (8.8) | 1 (2.9) | 4 (5.9) |
 Alanine aminotransferase increased | 1 (2.9) | 1 (2.9) | 2 (2.9) |
 Aspartate aminotransferase increased | 1 (2.9) | 0 | 1 (1.5) |